Treatment Patterns and Outcomes of Stage III Non-Small Cell Lung Cancer (NSCLC): Real World Evidence of How our Patients Fare

被引：1
作者：
Yusuf, D. [1 ]
Walton, R. [2 ]
Hurry, M. [2 ]
Cheung, W. [3 ,4 ]
机构：
[1] Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada
[2] Astrazeneca Canada, Mississauga, ON, Canada
[3] Univ Calgary, Med, Calgary, AB, Canada
[4] Alberta Hlth Serv, Calgary, AB, Canada
来源：
JOURNAL OF THORACIC ONCOLOGY | 2018年 / 13卷 / 10期
关键词：
outcomes; Treatments; NSCLC;
D O I：
10.1016/j.jtho.2018.08.967
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.15-34
引用
收藏
页码：S626 / S626
页数：1
相关论文
共 50 条
  • [31] Real-World Treatment Patterns and Timeliness of Clinical Care Pathway for Non-Small Cell Lung Cancer Patients in Austria: The PRATER Retrospective Study
    Hochmair, Maximilian
    Terbuch, Angelika
    Lang, David
    Trockenbacher, Christian
    Augustin, Florian
    Ghanim, Bahil
    Maurer, Dominik
    Taghizadeh, Hossein
    Kamhuber, Christoph
    Wurm, Robert
    Lindenmann, Joerg
    Braz, Petra
    Bundalo, Tatjana
    Begic, Merjem
    Bauer, Johanna
    Reimann, Patrick
    Mueser, Nino
    Huemer, Florian
    Schlintl, Verena
    Bianconi, Daniela
    Baumgartner, Bernhard
    Schenk, Peter
    Rauter, Markus
    Hoetzenecker, Konrad
    CANCERS, 2024, 16 (14)
  • [32] The role of biomarkers in stage III non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    Ito, Masaoki
    Santarpia, Mariacarmela
    Aguilar, Andres
    Codony-Servat, Jordi
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (06) : 469 - 480
  • [33] Two-stage treatment of non-small cell lung cancer (NSCLC) in patients with severe coronary heart disease
    Reshetov, Aleksey
    Nikolaev, German
    Elkin, Aleksey
    Snepanov, Sergey
    Ermakov, Dmitriy
    Klimenko, Vasiliy
    EUROPEAN RESPIRATORY JOURNAL, 2019, 54
  • [34] Variation in the time to treatment for stage III and IV non-small cell lung cancer patients for hospitals in the Netherlands
    van de Ven, M.
    Retel, V. P.
    Koffijberg, H.
    van Harten, W. H.
    IJzerman, M. J.
    LUNG CANCER, 2019, 134 : 34 - 41
  • [35] Real-world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non-small cell lung cancer
    Huang, Yiqing
    Zhao, Joseph J.
    Soon, Yu Yang
    Wong, Alvin
    Aminkeng, Folefac
    Ang, Yvonne
    Asokumaran, Yugarajah
    Low, Jia Li
    Lee, Matilda
    Choo, Joan R. E.
    Chan, Gloria
    Kee, Adrian
    Tay, Sen Hee
    Goh, Boon Cher
    Soo, Ross A.
    THORACIC CANCER, 2022, 13 (22) : 3152 - 3161
  • [36] Gemcitabine in non-small cell lung cancer (NSCLC)
    Manegold, C
    Zatloukal, P
    Krejcy, K
    Blatter, J
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (01) : 29 - 42
  • [37] Micrometastases in non-small cell lung cancer (NSCLC)
    Passlick, B
    LUNG CANCER, 2001, 34 : S25 - S29
  • [38] Real-World Experience of Consolidation Durvalumab for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
    Barbaro, A.
    Mienko, F.
    Deng, L.
    Ohri, N.
    Halmos, B.
    Perez-Soler, R.
    Gucalp, R.
    Bodner, W.
    Cheng, H.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S906 - S907
  • [39] Our experience with crizotinib in the treatment of non-small cell lung cancer
    Aksel, Nimet
    Gayaf, Mine
    Ari, Gulsum
    Akyol, Murat
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [40] Patterns of Treatment and Real-World Outcomes of Patients With Non-small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations Receiving Mobocertinib: The EXTRACT Study
    Liu, Geoffrey
    Nyaw, Shi Feng
    Mok, Tony S. K.
    Curcio, Hubert
    Cortot, Alexis B.
    Kam, Tsz Yeung
    Descourt, Renaud
    Chik, Yin Kwan
    Cheema, Parneet
    Gwinnutt, James M.
    Churchill, Eric N.
    Nyborn, Justin
    Curran, Eileen
    Savell, Alexandra
    Yin, Yu
    Chong, Katie
    Tanaka-Chambers, Yuka
    Kretz, Julian
    Cadranel, Jacques
    CANCER MEDICINE, 2025, 14 (03):
12345